Biopsies from adult patients enrolled in either the Database study or pretreatment biopsies from the adult treatment trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with NASH) (PIVENS) were reviewed in a standardized blinded fashion by the Pathology Committee of the NASH CRN, composed of a pathologist from each of the 8 clinical centers, and one from the National Cancer Institute. Assignment of a diagnostic category was based on consensus recognition of the distinctive features of SH independent of the degree of NAFLD severity as indicated by the NAS. Biopsies that had been classified by the Pathology Committee during Central Review as “cirrhosis with or without features of NAFLD or NASH” were excluded from this analysis, as it is well recognized that the active lesions of steatohepatitis may not be retained in cirrhosis. Biopsies with the zone 1 borderline pattern were also excluded as this is a pattern that most commonly occurs in pediatric NAFLD and was rare among our adult cases. When more than one biopsy for a subject was available, only the first biopsy was used in the analysis. Histologic and clinical data were analyzed as described below.
>
Chemicals & Drugs
>
Organic Chemical
>
Pioglitazone
Pioglitazone
Pioglitazone is an oral antidiabetic medication used to improve glycemic control in patients with type 2 diabetes mellitus.
It belongs to the thiazolidinedione class of drugs and acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhancing insulin sensitivity and reducing insulin resistance.
Pioglitazone may be used alone or in combination with other antidiabetic agents to manage hyperglycemia.
Its efficacy and safety have been extensively studied, though its use has been associated with some potential adverse effects, such as weight gain, edema, and an increased risk of bladder cancer.
Researchers can leverage PubCompare.ai's AI-driven protocol comparison tool to optimize their Pioglitazone research, easily locate the best protocols from literature, preprints, and patents, and improve the reproducibility and accuracy of their studies.
It belongs to the thiazolidinedione class of drugs and acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, enhancing insulin sensitivity and reducing insulin resistance.
Pioglitazone may be used alone or in combination with other antidiabetic agents to manage hyperglycemia.
Its efficacy and safety have been extensively studied, though its use has been associated with some potential adverse effects, such as weight gain, edema, and an increased risk of bladder cancer.
Researchers can leverage PubCompare.ai's AI-driven protocol comparison tool to optimize their Pioglitazone research, easily locate the best protocols from literature, preprints, and patents, and improve the reproducibility and accuracy of their studies.
Most cited protocols related to «Pioglitazone»
Adult
Biopsy
Cirrhosis
Diagnosis
Non-alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Pathologists
Patients
Pioglitazone
Placebos
Steatohepatitis
Vitamin E
Adult
Alcohol Use Disorder
Antibodies, Antinuclear
Autoimmune Chronic Hepatitis
Child
Ethanol
Fibrosis
Hemochromatosis
Hepatitis B
Hepatolenticular Degeneration
Hypergammaglobulinemia
Liver Diseases
Metformin
Necrosis
Non-alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Pioglitazone
Placebos
Primary Biliary Cholangitis
SERPINA5 protein, human
TimeLine
Vitamin E
Woman
Adult
Biopsy
Eligibility Determination
Fibrosis
Hepatocyte
Inflammation
Injuries
Liver
Non-alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Patients
Pioglitazone
Placebos
Steatohepatitis
Therapeutics
Vitamin E
The present study was approved by the institutional review board and written informed consent was obtained from all patients. This study is registered with the University Hospital Medical Information Network (UMIN) clinical trials registry, number UMIN 000001948. All subjects were female type 2 diabetes patients aged 20–75 years at screening, because edema was observed more frequently in females than in males3 . Patients with congestive heart failure, severe ketosis and type 1 diabetes were excluded. Other exclusion criteria were pregnancy or the possibility of becoming pregnant. Having a history of congestive heart failure, a severe hepatic or renal dysfunction, a severe infection or injury, and an allergic history of pioglitazone were also exclusion criteria.
We analyzed salt excretion, blood pressure, bodyweight, several clinical parameters and conforming with or without edema before and after 8 weeks of administration of pioglitazone at 15 mg/day, reflecting dosage commonly recommended in Japan3 . Edema was clinically diagnosed by the presence of pitting after pressure was applied to the bilateral lower extremities. Before administration, they were asked to measure daily salt excretion by using a salt monitoring system to measure salt in overnight urine4 . Specifically, before going to bed, they voided completely and discarded the urine. Overnight urine was collected in a 1‐L urine cup. After awakening, they voided and placed the urine in the urine cup, adding any urine they had voided overnight. Then they set the salt monitor and recorded the display value4 . Also, they were asked to measure their blood pressure daily for 21 days. We then evaluated whether a significant correlation was found between salt excretion and blood pressure (correlation coefficient >0.4, P < 0.05)4 . We asked the participants not to change their lifestyle, including foods, salt intake and daily physical activity, and all medications, including anti‐hypertensive drugs, during the study.
Results are expressed as means ± SD. Differences between two groups were analyzed for statistical significance by Student’s t‐test for unpaired comparisons. Paired analyses within groups were carried out using paired t‐test or Wilcoxon signed‐rank test as appropriate. Individual comparisons among three groups were assessed with the Kruskal–Wallis test.
We analyzed salt excretion, blood pressure, bodyweight, several clinical parameters and conforming with or without edema before and after 8 weeks of administration of pioglitazone at 15 mg/day, reflecting dosage commonly recommended in Japan
Results are expressed as means ± SD. Differences between two groups were analyzed for statistical significance by Student’s t‐test for unpaired comparisons. Paired analyses within groups were carried out using paired t‐test or Wilcoxon signed‐rank test as appropriate. Individual comparisons among three groups were assessed with the Kruskal–Wallis test.
Antihypertensive Agents
Blood Pressure
Body Weight
Congestive Heart Failure
Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent
Edema
Ethics Committees, Research
Females
Food
Infection
Injuries
Ketosis
Kidney Failure
Lower Extremity
Patients
Pharmaceutical Preparations
Physical Examination
Pioglitazone
Pregnancy
Pressure
Sodium Chloride, Dietary
Student
Urine
Woman
Animals
Animals, Laboratory
Caimans
Ethanol
Fetal Alcohol Syndrome
Infant, Newborn
Institutional Animal Care and Use Committees
Intralipid
Mice, House
Patient Holding Stretchers
Pharmaceutical Preparations
Pioglitazone
Tissues
Most recents protocols related to «Pioglitazone»
After the determination of MTC, the hyperglycemic zebrafish model was established as described in section “2.8.1. Determination of maximum detection concentration.” The zebrafish without any treatment was taken as normal group. The zebrafish treated with 500, 1,000, and 2,000 μg/ml of E70 PRA extract were taken as treatment groups, while the zebrafish treated with 18 μg/ml pioglitazone (PGTZ) was used as positive control. The blood glucose level (G) was determined with blood glucose meter, the hypoglycemic effect was calculated as follows:
Full text: Click here
Blood Glucose
Hypoglycemic Effect
Pioglitazone
Zebrafish
All of the studies performed were approved by the University of Kentucky Institutional Animal Care and Use Committee, in compliance with the guidelines of the Association for the Assessment and Accreditation for Laboratory Animal Care, International and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.12 Animal experiments complied with Animal Research: Reporting of In Vivo Experiments guidelines. All experiments were conducted using male C57BL/6J mice (2–3 months old; Jackson Laboratories, Bar Harbor, ME, USA).
The animals were housed five per cage, maintained in a 14 h light/10 h dark cycle, fed a balanced diet ad libitum. Animals were randomly assigned to groups, based on injury designation (sham or CCI) and treatment designation (vehicle or pioglitazone). Treatments were given in random order. All experimentation was performed blinded to treatment groups. For all outcomes, experiments were conducted with biological replicates of N = 4–8/group. Additionally, technical triplets were used in each assay.
Two separate cohorts were used for this study. The acute study was conducted to examine the effect of pioglitazone treatment after mild brain contusion on total, glia-enriched, and synaptic mitochondrial bioenergetic measures in the brain. Experimental groups for the acute study were euthanized at 48 h after injury. The subacute efficacy study was conducted to examine how modulation of acute mitochondrial bioenergetics with pioglitazone translated into cortical neuroprotection after mild brain contusion. Experimental groups for the subacute efficacy study were euthanized at 15 days after injury. Mice received a bolus (i.p.) administration of pioglitazone (100 µL volume; 1:1 DMSO and PEG400) at either 0.25, 3, 12, or 24 h after mild CCI, based on the treatment strategy outlined in Hubbard et al.4 (link) The 15-day efficacy study utilized 7-day duration Alzet Mini Pump 1007D (release of 0.5 µL/h; Alzet, Cupertino, CA, USA).
The animals were housed five per cage, maintained in a 14 h light/10 h dark cycle, fed a balanced diet ad libitum. Animals were randomly assigned to groups, based on injury designation (sham or CCI) and treatment designation (vehicle or pioglitazone). Treatments were given in random order. All experimentation was performed blinded to treatment groups. For all outcomes, experiments were conducted with biological replicates of N = 4–8/group. Additionally, technical triplets were used in each assay.
Two separate cohorts were used for this study. The acute study was conducted to examine the effect of pioglitazone treatment after mild brain contusion on total, glia-enriched, and synaptic mitochondrial bioenergetic measures in the brain. Experimental groups for the acute study were euthanized at 48 h after injury. The subacute efficacy study was conducted to examine how modulation of acute mitochondrial bioenergetics with pioglitazone translated into cortical neuroprotection after mild brain contusion. Experimental groups for the subacute efficacy study were euthanized at 15 days after injury. Mice received a bolus (i.p.) administration of pioglitazone (100 µL volume; 1:1 DMSO and PEG400) at either 0.25, 3, 12, or 24 h after mild CCI, based on the treatment strategy outlined in Hubbard et al.4 (link) The 15-day efficacy study utilized 7-day duration Alzet Mini Pump 1007D (release of 0.5 µL/h; Alzet, Cupertino, CA, USA).
Full text: Click here
Animals
Animals, Laboratory
Bioenergetics
Biological Assay
Biopharmaceuticals
Brain
Brain Contusion
Cortex, Cerebral
Diet
Injuries
Institutional Animal Care and Use Committees
Males
Mice, House
Mice, Inbred C57BL
Mitochondria
Neuroglia
Neuroprotection
Pioglitazone
polyethylene glycol 400
Sulfoxide, Dimethyl
Triplets
We searched electronic databases of PubMed, EMBASE, and Web of Science via specific strategies using the keywords “treatment”, “therapy”, “intervention”, “polycystic ovary syndrome” and “randomized controlled trial” to Nov 2021. The detailed search strategy have been listed in Supplementary Table 1 .
The included articles met the following criteria: 1) The studies were placebo-controlled or head-to-head RCTs enrolling women who were infertile due to PCOS and did not have diabetes, hyperprolactinemia, thyroid disorders, late-onset congenital adrenal hyperplasia, or Cushing’s syndrome. 2) The studies included at least one of the following interventions: CC, LZ, MET, TZDs (pioglitazone (PIO) or rosiglitazone (ROS)), GLP1-RA. 3) The studies must report the clinical pregnancy number in each group, but not the pregnancy rate per cycle. Clinical pregnancy must have been identified with ultrasound detection of fetal heartbeats.
Studies with the following conditions were excluded: 1) trials that used human chorionic gonadotropin (hCG) or other gonadotropins since they are not first-line treatments. 2) Studies that conducted surgical treatments. 3) Studies in which different medicines were given consecutively according to the individual’s response to the drugs, resulting in different treatments among the study groups. 4) Non-English articles or those without the full text available were not included.
Two reviewers independently screened the titles, abstracts and full texts. Disagreements were resolved by consultation with a third reviewer.
The included articles met the following criteria: 1) The studies were placebo-controlled or head-to-head RCTs enrolling women who were infertile due to PCOS and did not have diabetes, hyperprolactinemia, thyroid disorders, late-onset congenital adrenal hyperplasia, or Cushing’s syndrome. 2) The studies included at least one of the following interventions: CC, LZ, MET, TZDs (pioglitazone (PIO) or rosiglitazone (ROS)), GLP1-RA. 3) The studies must report the clinical pregnancy number in each group, but not the pregnancy rate per cycle. Clinical pregnancy must have been identified with ultrasound detection of fetal heartbeats.
Studies with the following conditions were excluded: 1) trials that used human chorionic gonadotropin (hCG) or other gonadotropins since they are not first-line treatments. 2) Studies that conducted surgical treatments. 3) Studies in which different medicines were given consecutively according to the individual’s response to the drugs, resulting in different treatments among the study groups. 4) Non-English articles or those without the full text available were not included.
Two reviewers independently screened the titles, abstracts and full texts. Disagreements were resolved by consultation with a third reviewer.
Full text: Click here
Cushing Syndrome
Diabetes Mellitus
EHMT1 protein, human
Fetal Ultrasonography
Gonadotropins
Head
Human Chorionic Gonadotropin
Hyperprolactinemia
Late-onset congenital adrenal hyperplasia
Operative Surgical Procedures
Pharmaceutical Preparations
Pioglitazone
Placebos
Polycystic Ovary Syndrome
Pregnancy
Pulse Rate
Rosiglitazone
Thyroid Diseases
Woman
We used propensity-score matching to optimize the relevant covariates between TZD users and nonusers (D’Agostino, 1998 (link)). The propensity score for each participant was estimated using non-parsimonious multivariable logistic regression, with TZD use as the dependent variable. We included 35 clinically related covariates as independent variables (Table 1 ). The nearest-neighbor algorithm was adopted to construct matched pairs, assuming the standardized mean difference (SMD) value <0.1 to be a negligible difference between the study and comparison cohorts.
We used crude and multivariable-adjusted Cox proportional hazards models to compare outcomes between TZD users and nonusers. The results were presented as hazard ratios (HRs) and 95% confidence intervals (CIs) for TZD users compared with nonusers. This study is based on the intention-to-treat hypothesis. To calculate the observed risks, we censored the participants until the date of respective outcomes, death, or at the end of follow-up on December 31, 2018, whichever came first. The Kaplan–Meier method and log-rank tests were used to compare the cumulative incidences of hospitalization for all-cause pneumonia, bacterial pneumonia, IMV, and death due to pneumonia during the follow-up time between TZD users and nonusers. We compared the risk of hospitalization for all-cause pneumonia among different subgroups of age, sex, comorbidities, medications (rosiglitazone, pioglitazone, and others) for clinical applicability of results. We also assessed the cumulative duration (<153, 153–549, ≧550 days) and dose (<2,940, 2,940–10,009, ≧10,110 mg) of pioglitazone for the risks of hospitalization for all-cause pneumonia, bacterial pneumonia, IMV, and death due to pneumonia compared with no-use of TZDs to explore the dose relationship. We performed a stratified analysis to see the effect of TZD vs. non-TZD in the risk of all-cause pneumonia stratified by the subgroups of metformin use vs. no-use, SU use vs. no-use, DPP-4 inhibitor use-vs. no-use trying to determine whether other hypoglycemic agents have effect on pneumonia risk; stratified by patient’s resident areas of the Northern, Central, Southern, and Eastern Taiwan trying to see whether the different environmental exposures have different effect on pneumonia risk.
A two-tailed value of p <0.05 was considered significant. SAS (version 9.4; SAS Institute, Cary, NC, United States) was used for statistical analysis.
We used crude and multivariable-adjusted Cox proportional hazards models to compare outcomes between TZD users and nonusers. The results were presented as hazard ratios (HRs) and 95% confidence intervals (CIs) for TZD users compared with nonusers. This study is based on the intention-to-treat hypothesis. To calculate the observed risks, we censored the participants until the date of respective outcomes, death, or at the end of follow-up on December 31, 2018, whichever came first. The Kaplan–Meier method and log-rank tests were used to compare the cumulative incidences of hospitalization for all-cause pneumonia, bacterial pneumonia, IMV, and death due to pneumonia during the follow-up time between TZD users and nonusers. We compared the risk of hospitalization for all-cause pneumonia among different subgroups of age, sex, comorbidities, medications (rosiglitazone, pioglitazone, and others) for clinical applicability of results. We also assessed the cumulative duration (<153, 153–549, ≧550 days) and dose (<2,940, 2,940–10,009, ≧10,110 mg) of pioglitazone for the risks of hospitalization for all-cause pneumonia, bacterial pneumonia, IMV, and death due to pneumonia compared with no-use of TZDs to explore the dose relationship. We performed a stratified analysis to see the effect of TZD vs. non-TZD in the risk of all-cause pneumonia stratified by the subgroups of metformin use vs. no-use, SU use vs. no-use, DPP-4 inhibitor use-vs. no-use trying to determine whether other hypoglycemic agents have effect on pneumonia risk; stratified by patient’s resident areas of the Northern, Central, Southern, and Eastern Taiwan trying to see whether the different environmental exposures have different effect on pneumonia risk.
A two-tailed value of p <0.05 was considered significant. SAS (version 9.4; SAS Institute, Cary, NC, United States) was used for statistical analysis.
Full text: Click here
Dipeptidyl-Peptidase IV Inhibitors
Environmental Exposure
Hospitalization
Hypoglycemic Agents
Metformin
Patients
Pharmaceutical Preparations
Pioglitazone
Pneumonia
Pneumonia, Bacterial
Rosiglitazone
This double-blind, randomized, placebo-controlled clinical trial was performed on 92 patients with T2D and nephropathy that referred to the Isfahan Endocrine and Metabolism Research Center from November 2019 to April 2021.
Inclusion criteria consisted of T2D patients age ≥ 18 years, and microalbuminuria (urine albumin-creatinine ratio (UACR) of 30–300 mg/g (in three urine samples collected consecutively over two weeks before the beginning of the study) with or without GFR reduction (less than 60)), glycated hemoglobin (HbA1c) level of 6.5–10% (48–86 mmol/mol), body mass index (BMI) of less than 40 kg/m2.
Furthermore, patients who were taking short-acting insulins, rosiglitazone, pioglitazone, GLP-1 receptor analogues, sodium glucose co-transporter 2 inhibitors or anti-obesity drugs within three months before the beginning of the study, those with a history of myocardial infarction, stroke, or transient ischemic attack within 6 months of the beginning of the study, patients who had non-diabetic renal failure or urinary tract infection, or those who had received a kidney transplant were not included in the study. They were excluded the study, in the case of not cooperating, not attending in the follow-up sessions, or showing drug-induced complications.
Inclusion criteria consisted of T2D patients age ≥ 18 years, and microalbuminuria (urine albumin-creatinine ratio (UACR) of 30–300 mg/g (in three urine samples collected consecutively over two weeks before the beginning of the study) with or without GFR reduction (less than 60)), glycated hemoglobin (HbA1c) level of 6.5–10% (48–86 mmol/mol), body mass index (BMI) of less than 40 kg/m2.
Furthermore, patients who were taking short-acting insulins, rosiglitazone, pioglitazone, GLP-1 receptor analogues, sodium glucose co-transporter 2 inhibitors or anti-obesity drugs within three months before the beginning of the study, those with a history of myocardial infarction, stroke, or transient ischemic attack within 6 months of the beginning of the study, patients who had non-diabetic renal failure or urinary tract infection, or those who had received a kidney transplant were not included in the study. They were excluded the study, in the case of not cooperating, not attending in the follow-up sessions, or showing drug-induced complications.
Full text: Click here
Albumins
Anti-Obesity Agents
Cerebrovascular Accident
Creatinine
Glucagon-Like Peptide-1 Receptor
Hemoglobin, Glycosylated
Index, Body Mass
Insulin, Short-Acting
Kidney Diseases
Kidney Failure
Kidney Transplantation
Metabolism
Myocardial Infarction
Patients
Pharmaceutical Preparations
Pioglitazone
Placebos
Rosiglitazone
Sodium-Glucose Transporter 2 Inhibitors
System, Endocrine
Transient Ischemic Attack
Urinary Tract Infection
Urine
Top products related to «Pioglitazone»
Sourced in United States, United Kingdom, Germany, China, Sao Tome and Principe
Pioglitazone is a laboratory equipment product manufactured by Merck Group. It is a chemical compound used for various research and analytical applications in scientific laboratories. The core function of Pioglitazone is to serve as a standard or reference material for testing and calibration purposes.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States
Pioglitazone is a chemical compound used in research and laboratory settings. It is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist. Pioglitazone can be used as a reference standard or for the development of analytical methods.
Sourced in United States, Germany, United Kingdom, China, Macao
GW9662 is a laboratory equipment product manufactured by Merck Group. It is a selective and irreversible antagonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ).
Sourced in United States, Germany, United Kingdom, China, France, Canada, Italy, Sao Tome and Principe, Japan, Switzerland, Macao, Israel, Australia, Spain, Austria, Sweden, Poland, Denmark, New Zealand, Belgium, Portugal, Ireland, Netherlands, Brazil, Colombia, India, Morocco, Argentina
Insulin is a lab equipment product designed to measure and analyze insulin levels. It provides accurate and reliable results for research and diagnostic purposes.
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Sao Tome and Principe, Macao, France, Australia, Switzerland, Canada, Denmark, Spain, Israel, Belgium, Ireland, Morocco, Brazil, Netherlands, Sweden, New Zealand, Austria, Czechia, Senegal, Poland, India, Portugal
Dexamethasone is a synthetic glucocorticoid medication used in a variety of medical applications. It is primarily used as an anti-inflammatory and immunosuppressant agent.
Sourced in United States, Germany, China, France, Macao, Italy, Sao Tome and Principe
Rosiglitazone is a synthetic compound used as a laboratory reagent. It is a member of the thiazolidinedione class of drugs and functions as a selective agonist for the peroxisome proliferator-activated receptor gamma (PPAR-gamma). Rosiglitazone is commonly used in research studies to investigate its effects on cellular and metabolic processes.
Sourced in United States
GW9662 is a synthetic organic compound that functions as a selective and irreversible peroxisome proliferator-activated receptor gamma (PPARγ) antagonist.
Sourced in United States, Germany, China, United Kingdom, Sao Tome and Principe, Macao, Italy, Japan, Canada, France, Switzerland, Israel, Australia, Spain, India, Ireland, Brazil, Poland, Netherlands, Sweden, Denmark, Hungary, Austria, Mongolia
The LPS laboratory equipment is a high-precision device used for various applications in scientific research and laboratory settings. It is designed to accurately measure and monitor specific parameters essential for various experimental procedures. The core function of the LPS is to provide reliable and consistent data collection, ensuring the integrity of research results. No further details or interpretations can be provided while maintaining an unbiased and factual approach.
Sourced in Japan, United States
Pioglitazone is a pharmaceutical product used for the measurement and analysis of chemical compounds. It is a key component in various laboratory equipment and instrumentation.
More about "Pioglitazone"
Pioglitazone is a powerful oral antidiabetic medication used to enhance glycemic control in patients with type 2 diabetes mellitus.
It belongs to the thiazolidinedione class of drugs and acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, which improves insulin sensitivity and reduces insulin resistance.
Pioglitazone can be used alone or in combination with other antihyperglycemic agents to effectively manage hyperglycemia.
Its efficacy and safety have been extensively studied, though its use has been associated with potential adverse effects like weight gain, edema, and an increased risk of bladder cancer.
Researchers can leverage the AI-driven protocol comparison tool from PubCompare.ai to optimize their Pioglitazone research.
This powerful tool can help them easily locate the best protocols from literature, preprints, and patents, improving the reproducibility and accuracy of their Pioglitazone studies.
The tool's intelligent comparison capabilities allow researchers to experience the full power of AI-driven research for their Pioglitazone-related projects.
Closely related terms and concepts include FBS (fasting blood sugar), GW9662 (a PPAR-γ antagonist), Insulin (a key hormone regulating glucose metabolism), Dexamethasone (a synthetic glucocorticoid), Rosiglitazone (another thiazolidinedione drug), and LPS (lipopolysaccharide, which can induce insulin resistance).
Leveraging these related topics can provide a more comprehensive understanding of Pioglitazone's mechanisms of action and its role in managing type 2 diabetes mellitus.
It belongs to the thiazolidinedione class of drugs and acts as a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, which improves insulin sensitivity and reduces insulin resistance.
Pioglitazone can be used alone or in combination with other antihyperglycemic agents to effectively manage hyperglycemia.
Its efficacy and safety have been extensively studied, though its use has been associated with potential adverse effects like weight gain, edema, and an increased risk of bladder cancer.
Researchers can leverage the AI-driven protocol comparison tool from PubCompare.ai to optimize their Pioglitazone research.
This powerful tool can help them easily locate the best protocols from literature, preprints, and patents, improving the reproducibility and accuracy of their Pioglitazone studies.
The tool's intelligent comparison capabilities allow researchers to experience the full power of AI-driven research for their Pioglitazone-related projects.
Closely related terms and concepts include FBS (fasting blood sugar), GW9662 (a PPAR-γ antagonist), Insulin (a key hormone regulating glucose metabolism), Dexamethasone (a synthetic glucocorticoid), Rosiglitazone (another thiazolidinedione drug), and LPS (lipopolysaccharide, which can induce insulin resistance).
Leveraging these related topics can provide a more comprehensive understanding of Pioglitazone's mechanisms of action and its role in managing type 2 diabetes mellitus.